The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers (EGRABINS1)
Stroke
About this trial
This is an interventional treatment trial for Stroke focused on measuring Cerebrovascular Stroke, Ischemic Stroke, Glucagon like peptide - 1
Eligibility Criteria
Inclusion Criteria:
- Person ≥ 50 years of age
- Has given written informed consent
Exclusion Criteria:
- Intracerebral haemorrhage
- Subdural / epidural hemorrhage
- subarachnoid haemorrhage
- previously major structural damage to the brain (eg. sequelae after large stroke or brain surgery)
- Diabetes type 1
- Diabetes type 2
- Known atrial fibrillation
- > 50% stenosis of internal carotid
- Known allergy to GLP-1 receptor agonists
- Hepatic impairment (ALT> 3 x upper normal limit)
- Renal impairment (eGFR <30 ml / min)
- Inflammatory bowel disease
- Previous pancreatitis
- Heart failure (NYHA class 3-4)
- Pregnancy or lactation
- Patient not expected to co-operate to the investigations
- Visualization of the middle cerebral artery bilaterally by transcranial doppler not possible
Sites / Locations
- Department of Neurology, Herlev-Gentofte Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Byetta
Isotonic saline
Pre- and post treatment investigations: Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler Cerebral cortical oxygination by near infrared spectroscopy (NIRS) Endothelial function/response by the methods: Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA) EndoPAT2000 Ankle-brachial index
Pre- and post treatment investigations: Mean flow velocity of the middle cerebral arteries bilateral by transcranial doppler Cerebral cortical oxygination by near infrared spectroscopy (NIRS) Endothelial function/response by the methods: Biomarkers in blood (eg. e-selectin, VCAM, ICAM, endothelin, ADMA, miRNA) EndoPAT2000 Ankle-brachial index